Table 2. Odds ratios for breast cancer risk by tumor grade*.
Locus | Grade 1 | Grade 2 | Grade 3 | Obs. | Adj. | ||||||||
SNP | Genotype | Controls | N | OR** | 95% CI | N | OR** | 95% CI | N | OR** | 95% CI | P*** | P**** |
FGFR2 | GG | 8916 | 979 | 1.00 | 2368 | 1.00 | 1686 | 1.00 | |||||
rs2981582 | AG | 10988 | 1627 | 1.32 | 1.21–1.43 | 3879 | 1.31 | 1.24–1.39 | 2344 | 1.12 | 1.04–1.20 | ||
AA | 3389 | 696 | 1.83 | 1.64–2.03 | 1521 | 1.68 | 1.55–1.81 | 853 | 1.32 | 1.20–1.44 | |||
per allele | 1.35 | 1.28–1.42 | 1.30 | 1.25–1.35 | 1.14 | 1.09–1.19 | 10−8 | <0.001 | |||||
TNRC9 | GG | 12073 | 1497 | 1.00 | 3620 | 1.00 | 2382 | 1.00 | |||||
rs3803662 | AG | 8570 | 1436 | 1.31 | 1.21–1.42 | 3285 | 1.26 | 1.19–1.33 | 1978 | 1.15 | 1.08–1.23 | ||
AA | 1648 | 340 | 1.49 | 1.31–1.70 | 775 | 1.45 | 1.32–1.59 | 471 | 1.33 | 1.19–1.49 | |||
per allele | 1.25 | 1.19–1.33 | 1.22 | 1.18–1.27 | 1.16 | 1.10–1.21 | 0.018 | 0.50 | |||||
MAP3K1 | TT | 12218 | 1650 | 1.00 | 3890 | 1.00 | 2478 | 1.00 | |||||
rs889312 | GT | 9316 | 1371 | 1.12 | 1.04–1.21 | 3217 | 1.11 | 1.05–1.17 | 1997 | 1.07 | 1.00–1.15 | ||
GG | 1767 | 267 | 1.18 | 1.03–1.36 | 679 | 1.26 | 1.15–1.39 | 429 | 1.23 | 1.09–1.38 | |||
per allele | 1.10 | 1.04–1.17 | 1.12 | 1.07–1.16 | 1.09 | 1.04–1.15 | 0.91 | 1.00 | |||||
8q24 | AA | 6794 | 940 | 1.00 | 2163 | 1.00 | 1505 | 1.00 | |||||
rs13281615 | AG | 9335 | 1456 | 1.15 | 1.05–1.26 | 3266 | 1.11 | 1.04–1.18 | 2063 | 1.01 | 0.94–1.09 | ||
GG | 3185 | 593 | 1.42 | 1.27–1.59 | 1329 | 1.35 | 1.25–1.47 | 783 | 1.14 | 1.03–1.26 | |||
per allele | 1.18 | 1.12–1.25 | 1.16 | 1.11–1.20 | 1.06 | 1.01–1.11 | 10−4 | 0.016 | |||||
LSP1 | AA | 11239 | 1549 | 1.00 | 3669 | 1.00 | 2287 | 1.00 | |||||
rs381798 | AG | 9923 | 1409 | 1.07 | 0.99–1.16 | 3314 | 1.04 | 0.99–1.10 | 2145 | 1.09 | 1.02–1.16 | ||
GG | 2100 | 333 | 1.24 | 1.09–1.41 | 792 | 1.21 | 1.10–1.32 | 476 | 1.17 | 1.04–1.30 | |||
per allele | 1.10 | 1.04–1.16 | 1.08 | 1.04–1.12 | 1.08 | 1.03–1.14 | 0.77 | 1.00 |
*: Analyses excluded data from three studies (MEC, NHS and TBCS) without information on tumor grade.
**: Per-allele OR adjusted for study.
***: P value for heterogeneity of ORs from case-only analyses adjusted by study.
****: Permutation adjusted P for heterogeneity